First-line gemcitabine and carboplatin in advanced ovarian carcinoma: A phase II study

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 113, Issue 12, 2006, Pages 1388-1392

  Tay, S K ^a   Ilanchadran, A ^b   Tan, T Y ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Anaemia; Anti tumour activity; Chemotherapy; Neutropenia; Thrombocytopenia

Indexed keywords

CARBOPLATIN; GEMCITABINE;

ADULT; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; FEMALE; HUMAN; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33750948812     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2006.01100.x     Document Type: Article

References (20)

1. Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001;82:532-7.
2. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Vermorken JB, et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991;27:1367-72.
3. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 1991;303:884-93.
4. Tay SK, Chang TC. An evaluation on the policy of routine treatment of advanced epithelial ovarian carcinoma by debulking surgery and combined platinum-cyclophosphomide chemotherapy in Singapore. Int J Gynecol Cancer 1996;6:44-8.
5. Hogberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001;40:340-60.
6. Neijt JP, Engelholm SA, Witteveen PO, Tuxen MK, Sorensen PG, Hansen M, et al. Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis. Semin Oncol 1997;24(5 Suppl 15):S15-36-39.
7. Mayerhofer K, Bodner-Adler B, Bodner K, Leodolter S, Kainz C. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity. Anticancer Res 2000;20:4047-50.
8. D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003;88:266-9.
9. Underhill CR, Parnis FX, Highley MS, Ahern J, Harper PG, Hansen H, et al. Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Anticancer Drugs 2001;12:647-52.
10. von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999;10:853-5.
11. Iaffaioli RV, Tortoriello A, Facchini G, Caponigro F, Gentile M, Marzano N, et al. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J Clin Oncol 1999;17:921-6.
12. Ng EW, Sandler AB, Robinson L, Einhorn LH. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study. Am J Clin Oncol 1999;22:550-3.
13. Favaretto AG, Aversa SM, Paccagnella A, Manzini Vde P, Palmisano V, Oniga F, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003;97:2791-7.
14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
15. du Bois A, Luck HJ, Meier W, Mobus V, Costa S, Richter B, et al. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynakologische Onkologie. Semin Oncol 1997;24(4 Suppl 11):28-33.
16. Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1991;11:251-63.
17. McGuire WP, Hoskin WJ, Brady MR, Kucera PR, Partridge EE, Look KY et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1-6.
18. Bauknecht T, Hefti A, Morack G, Villena-Heinsen C, Wallwiener D, Elling D, et al. Gemcitabine combined with cisplatin as first line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study. Int J Gynecol Cancer 2003;13:130-7.
19. Nogue M, Cirera L, Arcusa A, Batiste-Alentorn E, Balil A, Font A, et al. Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. Anticancer Drugs 2002;13:839-45.
20. Ozols RF. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Semin Oncol 1999;26(1 Suppl 2):84-9.